Thermo Fisher Scientific(US:TMO) ZACKSยท2025-01-30 15:36Core Insights - Thermo Fisher Scientific reported $11.4 billion in revenue for Q4 2024, a year-over-year increase of 4.7% [1] - The company's EPS for the same period was $6.10, up from $5.67 a year ago, exceeding the consensus EPS estimate of $5.93 by 2.87% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $11.25 billion, resulting in a surprise of 1.31% [1] Revenue Performance - Organic revenue growth was 4%, outperforming the average estimate of 2.5% based on five analysts [4] - Laboratory Products and Biopharma Services generated $5.94 billion, exceeding the four-analyst average estimate of $5.86 billion, with a year-over-year change of 3.8% [4] - Specialty Diagnostics revenue was $1.16 billion, slightly above the $1.15 billion average estimate, reflecting a 4.7% year-over-year increase [4] - Life Sciences Solutions reported $2.60 billion, compared to the $2.58 billion average estimate, marking a 5.5% year-over-year change [4] - Analytical Instruments revenue was $2.19 billion, surpassing the $2.14 billion estimate, with a year-over-year increase of 7.3% [4] - Eliminations accounted for -$487 million, slightly worse than the average estimate of -$472.26 million, but still showing a year-over-year change of 9.7% [4] Stock Performance - Thermo Fisher's shares returned 9.2% over the past month, significantly outperforming the Zacks S&P 500 composite's 1.2% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]